FDA U.S. FOOD & DRUG ADMINISTRATION
Complete Response Letter
Ryan Reynolds Atos-Syntel
Senior Associate Director, Division of Imaging and Radiation (DIRM)
FDA/CDER
Plot No. B-1 Software, Atos-Syntel Link Rd, MIDC Technology Park,
Talawade, Pimpri-Chinchwad, Maharashtra 411062
Dear Mr.Reynolds:
Please refer to your investigational new drug application (IND) submitted under section 505 of the Federal Food, Drug and Cosmetic Act for xxxxXX
We also refer to your amendment(s) dated December 3, 2021; April 2, 2022;
September 12, 2022; December 16, 2022 and January 12, 2023.
We have the following comments and requests for additional information. Please note that these requests are not clinical hold issues. However, response to them is requested:
Item#1:
Based on your submitted protocol CO-0000-001 and XXXXXXX Sub-protocol, it appears that you are pursuing a pathway intended to leverage XYXYXYXY investigation in support of new patient selection indication for XXXXXXXX. In approaching the design of downstream studies, we recommend that you focus on at least the following four high level considerations:
SECURE EMAIL Secure email is required for all email communications from FDA when confidential information (e.g., trade secrets, manufacturing, or patient information) is included in the message. To
US. Food and Drug Administration Silver Spring, MD 20993 www.fda.gov
IND 312321 :selected:
receive email communications from FDA that include confidential information (e.g., information requests, labeling revisions, courtesy copies of letters), you must establish secure email. To establish secure email with FDA, send an email request to SecureEmail@fda.hhs.gov. Please note that secure email may not be used for formal regulatory submissions to applications
Sincerely,
Ravindranath Tagore
3/21/2023 4:44:45 PM
Libo M., MD, PhD
Director
Division of Imaging and Radiation Medicine
Office of Specialty Medicine
Center for Drug Evaluation and Research
US. Food and Drug Administration Silver Spring, MD 20993 www.fda.gov